Theriva Biologics VIRAGE Trial in Pancreatic Cancer Published in Nature Medicine
Question
Theriva Biologics VIRAGE Trial in Pancreatic Cancer Published in Nature Medicine
Direct answer
Theriva Biologics announced the peer-reviewed publication of its Phase 2b VIRAGE trial results in Nature Medicine. The trial assessed VCN-01 combined with standard chemotherapy in metastatic pancreatic cancer, demonstrating gains across overall survival, progression-free survival, and response duration. — bullish pressure on TOVX.
- Original publisher
- Market Ontology
- Evidence through
- 2026-10-01
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-20
Cite as: Market Ontology, “Theriva Biologics VIRAGE Trial in Pancreatic Cancer Published in Nature Medicine”, revision 1, evidence through 2026-10-01. https://marketontology.com/catalysts/2026-10-01/theriva-biologics-virage-trial-in-pancreatic-cancer-published-in-nature-medicine-f20f4c
| Asset | Direction | Timeframe | Channel | Score |
|---|---|---|---|---|
| TOVX | ▲Bull | 1–5 days | Policy Shift | 65 |
Theriva Biologics VIRAGE Trial in Pancreatic Cancer Published in Nature Medicine
Theriva Biologics announced the peer-reviewed publication of its Phase 2b VIRAGE trial results in Nature Medicine. The trial assessed VCN-01 combined with standard chemotherapy in metastatic pancreatic cancer, demonstrating gains across overall survival, progression-free survival, and response duration. — bullish pressure on TOVX.
Theriva Biologics announced the peer-reviewed publication of its Phase 2b VIRAGE trial results in Nature Medicine. The trial assessed VCN-01 combined with standard chemotherapy in metastatic pancreatic cancer, demonstrating gains across overall survival, progression-free survival, and response duration.
- SummaryTheriva Biologics announced the peer-reviewed publication of its Phase 2b VIRAGE trial results in Nature Medicine. The trial assessed VCN-01 combined with standard chemotherapy in metastatic pancreatic cancer, demonstrating gains across overall survival, progression-free survival, and response duration.
- TOVXDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- TOVX closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- TOVX price vs. pre-event level
- TOVX volume vs. 20-day average
What happened next
Price follow-up pending — no stored daily closes for these assets yet.
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
No verifiable public source recorded for this card.
Related catalysts
- 2026-10-01Theriva Biologics Reports Phase 2b VIRAGE Survival Data in Nature MedicineTOVX
- 2026-10-01Theriva Biologics Publishes Phase 2b VIRAGE Pancreatic Cancer Data in Nature MedicineTOVX
- 2026-10-01Theriva Biologics VIRAGE Trial in Pancreatic Cancer Published in Nature MedicineTOVX
- 2026-10-01Theriva Biologics VIRAGE Phase 2b Data Published in Nature MedicineTOVX
- 2026-10-01Theriva Biologics VIRAGE Trial in Pancreatic Cancer Published in Nature MedicineTOVX
- 2026-10-01Theriva Biologics Publishes Positive Phase 2b Pancreatic Cancer DataTOVX
- 2026-10-01Theriva Biologics Reports Positive Phase 2b Pancreatic Cancer Data in NatureTOVX
- 2026-10-01Theriva Biologics Publishes Phase 2b VIRAGE data in Nature Medicine.TOVX
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.